NVIDIA Pushes AI Into Drug Development With Simulations Plus Collaboration - Yahoo Finance

NVIDIA has entered a strategic collaboration with Simulation Plus to apply GPU acceleration and AI-assisted workflows in drug development and quantitative systems pharmacology. This move extends NVIDI... Read original →

NVIDIA’s strategic collaboration with Simulation Plus signifies a pivotal shift in AI-driven drug discovery. By leveraging GPU acceleration and its BioNeMo platform, NVIDIA dramatically reduces computational time—by up to 75%—in complex modeling tasks like QSP and PK/PD, accelerating early-stage R&D. This move extends NVIDIA’s role beyond hardware into trusted scientific infrastructure, aligning with the broader trend of AI specialization in vertical domains. Competitively, NVIDIA is transitioning from a chip vendor to an end-to-end platform enabler in life sciences, reinforced by partnerships with IREN and Corning that integrate validated hardware-software ecosystems. Over time, such integrations could standardize AI-native workflows across pharma and CROs, embedding NVIDIA’s stack at the core of next-generation drug development and solidifying its leadership at the intersection of AI and computational biology.